Abivax S.A.
HealthcareNASDAQ:ABVX · NASDAQ Global Market
-$4.20 today
Vol 1.01M · Avg 1.57M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-73.9%
avg -189.4%
ROIC
-47.1%
avg -53.3%
ROA
-57.5%
avg -46.8%
Analysis
ROIC is currently the strongest return metric at -47.1% versus its period average of -53.3%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Marc de Garidel | Chief Executive Officer & Director | $1.32M | — | 68 | — | — |
Chris Rabbat | Vice President & Global Head of Medical Affairs | — | — | — | — | — |
Hema Keshava | Senior Vice President of Finance | — | — | — | — | — |
Kevin Shan | Vice President & Global Head of Biometrics | — | — | — | — | — |
Mary Mantock | Senior VP & Global Head of Regulatory Affairs | — | — | — | — | — |
Didier Blondel | EVP, CFO & Board Secretary | — | — | 62 | — | — |
Jerome Denis | Executive Vice President of Process Development & Manufacturing | — | — | — | — | — |
Patrick Malloy | Senior Vice President of Investor Relations | — | — | — | — | — |
Pierre Courteille | Chief Business Officer | — | — | 57 | — | — |
Ida Hatoum | Chief People & Compliance Officer | — | — | 51 | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | -10.6% | +150.1% (13yr)5 analysts |
| Net Income | N/A | N/A | N/A | N/A5 analysts |
| EBIT | N/A | N/A | N/A | N/A5 analysts |
Analysis
Recent growth has been strongest in Revenue at -10.6% over three years. Forward estimates point to Revenue at +150.1% (13yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Jazz Pharmaceuticals plc
NASDAQ:JAZZ
$14.62B
Axsome Therapeutics, Inc.
NASDAQ:AXSM
$13.22B
Madrigal Pharmaceuticals, Inc.
NASDAQ:MDGL
$11.05B
Nuvalent, Inc.
NASDAQ:NUVL
$9.07B
Corcept Therapeutics Incorporated
NASDAQ:CORT
$8.96B
Cytokinetics, Incorporated
NASDAQ:CYTK
$8.73B
Halozyme Therapeutics, Inc.
NASDAQ:HALO
$8.26B
Metsera, Inc.
MTSR
$7.43B
Merus N.V.
MRUS
$6.83B
Rhythm Pharmaceuticals, Inc.
NASDAQ:RYTM
$6.06B
Who manages ABVX?
Abivax S.A. (ABVX) lists 10 active executives. The top listed executive is Chris Rabbat, Vice President & Global Head of Medical Affairs.
Explore More
Continue the stock analysis
Jump to another research area for this company.